A detailed history of Woodline Partners LP transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 379,967 shares of AKRO stock, worth $16 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
379,967
Previous 292,468 29.92%
Holding current value
$16 Million
Previous $8.39 Million 25.98%
% of portfolio
0.08%
Previous 0.08%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$26.75 - $35.28 $2.34 Million - $3.09 Million
87,499 Added 29.92%
379,967 $10.6 Million
Q3 2024

Nov 14, 2024

BUY
$21.45 - $29.34 $1.97 Million - $2.7 Million
92,036 Added 45.92%
292,468 $8.39 Million
Q2 2024

Aug 14, 2024

BUY
$18.31 - $24.62 $1.32 Million - $1.77 Million
71,991 Added 56.05%
200,432 $4.7 Million
Q1 2024

May 15, 2024

BUY
$17.76 - $31.18 $2.28 Million - $4 Million
128,441 New
128,441 $3.24 Million

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.96B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.